Keyphrases
CB1 Receptor
100%
Parkinson's Disease
100%
Levodopa
100%
Cannabinoid Receptor Agonists
100%
6-Hydroxydopamine-lesioned Rats
100%
HU210
100%
Cannabinoid Receptor 1 (CB1R)
66%
Basal Ganglia
66%
Serotonin
33%
Rotational Motion
33%
Dopaminergic System
33%
Apomorphine
33%
Dopamine Receptor
33%
Cannabis
33%
Parkinson Patients
33%
Extrapyramidal System
33%
Glutamate
33%
Levodopa Therapy
33%
Neurotransmitters
33%
Tetrahydrocannabinol
33%
Co-expression
33%
Aminobutyric Acid
33%
N-methyl-D-aspartate Receptor Antagonist
33%
Chronic Neurodegeneration
33%
Cannabidiol
33%
Dopaminergic Neuron Loss
33%
Levodopa-carbidopa
33%
Primary Metabolites
33%
Voluntary Movement Control
33%
Synthetic Cannabinoids
33%
Endocannabinoids
33%
Neuroscience
Cannabinoid 1 Receptor
100%
Parkinson's Disease
100%
Receptor Agonists
100%
L-DOPA
100%
Oxidopamine
100%
Dexanabinol
100%
Dopaminergic
66%
Basal Ganglia
66%
Serotonin
33%
Behavior (Neuroscience)
33%
Agonist
33%
Gamma-Aminobutyric Acid
33%
Apomorphine
33%
Dopamine Receptor
33%
Cannabis
33%
Aspartic Acid
33%
Extrapyramidal System
33%
Neurotransmitter
33%
Glutamic Acid
33%
Tetrahydrocannabinol
33%
Neurodegenerative Disorder
33%
Cannabinoid Receptor Type 1
33%
Treatment of Parkinson's Disease
33%
Cannabinoid Receptor
33%
Carbidopa/Levodopa
33%
Aminobutyric Acid Derivative
33%
Endocannabinoid
33%
Cannabinoid
33%
Cannabidiol
33%
Pharmacology, Toxicology and Pharmaceutical Science
Levodopa
100%
Parkinson's Disease
100%
Oxidopamine
100%
Dexanabinol
100%
Cannabinoid 1 Receptor Agonist
100%
Dopamine Receptor Stimulating Agent
50%
Cannabinoid Receptor
50%
Degenerative Disease
25%
Serotonin
25%
Cannabis
25%
Glutamic Acid
25%
Aspartic Acid
25%
Neurotransmitter
25%
Tetrahydrocannabinol
25%
Dopamine Receptor
25%
4 Aminobutyric Acid
25%
Apomorphine
25%
Cannabidiol
25%
Endocannabinoid
25%
Aminobutyric Acid Derivative
25%
Carbidopa Plus Levodopa
25%
Cannabinoid
25%